Vega Clinic
Vega Clinic
Thailand, Bangkok
| Thailand | Turkey | Austria | |
| Stem cell therapy for ALS (amyotrophic lateral sclerosis) | from $25,000 / ฿850,000 | from $30,000 / ฿1,020,000 | from $60,000 / ฿2,040,000 |
| Stem Cell Therapy | from $1,800 / ฿61,200 | from $4,675 / ฿158,950 | from $8,500 / ฿289,000 |
| Plasmapheresis | from $2,200 / ฿74,800 | from $1,200 / ฿40,800 | from $2,000 / ฿68,000 |
Dr. PYONG integrates advanced robotics and non-invasive technologies to enhance neurorehabilitation outcomes at PYONG Rehabilitation Group.
Dr. Rak-areekul specializes in cognitive neurology and neurocognitive disorders, with a fellowship at King Chulalongkorn Memorial Hospital.
The doctor is a neurologist at Bumrungrad International Hospital with a medical degree from Siriraj Hospital, Mahidol University, Thailand. Board certified in neurology, the doctor has completed a fellowship in Vascular Neurology from Ramathibodi Hospital, Mahidol University. Special clinical interests include neurology and vascular neurology.
Dr. Pongwat Polpong is a top neurosurgeon and specialist in regenerative medicine in Thailand. He has more than 15 years of experience in clinical practice, teaching, and research. He trained at Siriraj Hospital, the Neurological Institute of Thailand, and the International Neuroscience Institute in Germany.
Dr. Pongwat has published many research papers on neurosurgery, parasitology, spine disorders, and brain diseases. His work includes studies on percutaneous endoscopic lumbar discectomy, cerebral cysticercosis, spinal cord injury, and cerebrovascular disorders.
He performed Bangkok Hospital Chanthaburi’s first endoscopic transsphenoidal surgery, a minimally invasive treatment for pituitary tumors. As Chief Physician at EDNA Wellness, he leads programs in Stem Cell Therapy, Neurology, Bone and Joint Regeneration, and Nutrition Enhancement.
Primary ALS treatment in Thailand focuses on multidisciplinary care at JCI-accredited facilities in Bangkok. Patients access FDA-approved medications like Riluzole alongside supportive therapies for respiratory and motor management. Modern protocols often integrate neurorehabilitation with advanced technologies like robotic gait training and mesenchymal stem cell applications.
Bookimed Expert Insight: While many search for experimental stem cell treatments, the real value in Thailand lies in its neurorehabilitation infrastructure. Facilities like Bumrungrad International Hospital serve over 500,000 international patients annually. They combine high-end technology with intensive physical therapy. Choosing a package that includes multiple nights of hospitalization allows for better initial monitoring of drug tolerance.
Patient Consensus: Patients emphasize the need to verify stem cell claims and suggest focusing on palliative support like ventilation. They recommend consulting neurologists at large private hospitals because these centers match international standards for standard ALS medication and nutrition support.
Stem cell therapy for ALS in Thailand aims to slow disease progression and improve quality of life. Clinics utilize mesenchymal stem cells for their neuroprotective properties. While considered experimental, these treatments are available at JCI-accredited facilities in Bangkok using intravenous and intrathecal delivery methods.
Bookimed Expert Insight: Success in Thailand often depends on combining cell therapy with intensive rehabilitation. Our data shows specialized centers like PYONG Rehabilitation Group focus on robotic gait training and neurorehabilitation. Choosing centers that integrate these technologies rather than standalone cell injections often leads to better functional stability. Dr. Kantaphong Thongrong at PYONG specifically uses wearable exoskeletons to maintain mobility during the treatment window.
Patient Consensus: Patients note that while the treatment may offer a temporary boost in energy, it is vital to manage expectations. Many stress the importance of following a strict neurorehabilitation routine afterward to maintain any motor function improvements gained during the trip.
Leading Thai hospitals like Bumrungrad International and Chulalongkorn Memorial provide recognized ALS care through specialized neuroscience departments. These facilities offer multidisciplinary support including neurology, rehabilitation, and palliative services. JCI-accredited centers in Bangkok utilize advanced imaging and international protocols to manage neurodegenerative symptoms.
Bookimed Expert Insight: While many search for experimental therapies, the real value in Thailand is the recovery infrastructure. Specialized providers like PYONG Rehabilitation Group focus on robotic gait training and hydrodissection. These advanced therapies help maintain mobility longer than standard physical therapy alone. This infrastructure is often more accessible in Bangkok than in many Western cities.
Patient Consensus: Patients note that navigating Bangkok traffic with limited mobility is difficult. Many suggest organizing home-based physiotherapy or choosing hospitals with inclusive transfers to minimize physical strain.
International patients choose Thailand for ALS management to access mesenchymal stem cell (MSC) therapies often unavailable in Western countries. Facilities like Bumrungrad International Hospital combine JCI-accredited neurology with advanced robotics. Many programs integrate neurorehabilitation, wearable exoskeleton training, and specialist-led palliative care protocols.
Bookimed Expert Insight: While many seek Thailand for experimental stem cell infusions, the real value lies in the integrated neurorehabilitation. Dr. Kantaphong Thongrong at PYONG Rehabilitation Group leads clinical use of wearable exoskeletons. This robotic gait training is rarely bundled with regenerative treatments elsewhere. Patients should prioritize clinics that offer these physical sessions alongside MSC therapy to maximize mobility outcomes.
Patient Consensus: Patients value Thailand for compassionate and low-stress palliative support. However, they strongly recommend verifying any clinic's success claims against international clinical trial databases before traveling for experimental stem cell procedures.